These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
441 related articles for article (PubMed ID: 17376311)
1. Induction of apoptosis in osteogenic sarcoma cells by combination of tumor necrosis factor-related apoptosis inducing ligand and chemotherapeutic agents. Sun J; Fu ZM; Fang CQ; Li JH Chin Med J (Engl); 2007 Mar; 120(5):400-4. PubMed ID: 17376311 [TBL] [Abstract][Full Text] [Related]
2. [Synergistic induction of apoptosis by the combination of TRAIL and low dose adriamycin in human osteosarcoma cell line U2OS]. Yang DS; Miao XD; Ye ZM; Xu YS Zhonghua Zhong Liu Za Zhi; 2005 Oct; 27(10):595-7. PubMed ID: 16438867 [TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Fan QL; Zou WY; Song LH; Wei W Cancer Chemother Pharmacol; 2005 Feb; 55(2):189-96. PubMed ID: 15290100 [TBL] [Abstract][Full Text] [Related]
5. Retrovirus-mediated transduction of TRAIL and chemotherapeutic agents co-operatively induce apoptotic cell death in both sarcoma and myeloma cells. Suzuki H; Hotta T; Koyama T; Komagata M; Imakiire A; Yanase N; Yoshimoto T; Mizuguchi J Anticancer Res; 2003; 23(4):3247-53. PubMed ID: 12926060 [TBL] [Abstract][Full Text] [Related]
6. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines. Mikami T; Koyama T; Koyama T; Imakiire A; Yamamoto K; Furuhata M; Toyota H; Mizuguchi J Anticancer Res; 2006; 26(2A):1153-60. PubMed ID: 16619517 [TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538 [TBL] [Abstract][Full Text] [Related]
8. Enhancement effect of adenovirus-mediated antisense c-myc and caffeine on the cytotoxicity of cisplatin in osteosarcoma cell lines. Xie XK; Yang DS; Ye ZM; Tao HM Chemotherapy; 2009; 55(6):433-40. PubMed ID: 19996588 [TBL] [Abstract][Full Text] [Related]
9. Ionizing radiation enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulations of death receptor 4 (DR4) and death receptor 5 (DR5) in human osteosarcoma cells. Hori T; Kondo T; Kanamori M; Tabuchi Y; Ogawa R; Zhao QL; Ahmed K; Yasuda T; Seki S; Suzuki K; Kimura T J Orthop Res; 2010 Jun; 28(6):739-45. PubMed ID: 20041491 [TBL] [Abstract][Full Text] [Related]
10. Enforced expression of a truncated form of Bax-alpha (tBax) driven by human telomerase reverse transcriptase (hTERT) promoter sensitizes tumor cells to chemotherapeutic agents or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Toyota H; Kondo S; Kyo S; Mizuguchi J Anticancer Res; 2006; 26(1A):99-105. PubMed ID: 16475685 [TBL] [Abstract][Full Text] [Related]
11. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice. Itashiki Y; Harada K; Ferdous T; Yoshida H Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Fang F; Wang AP; Yang SF Acta Pharmacol Sin; 2005 Nov; 26(11):1373-81. PubMed ID: 16225761 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer. Frese S; Schüller A; Frese-Schaper M; Gugger M; Schmid RA Anticancer Res; 2009 Aug; 29(8):2905-11. PubMed ID: 19661294 [TBL] [Abstract][Full Text] [Related]
14. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Wahl H; Tan L; Griffith K; Choi M; Liu JR Gynecol Oncol; 2007 Apr; 105(1):104-12. PubMed ID: 17174384 [TBL] [Abstract][Full Text] [Related]
15. 1-Methoxy-canthin-6-one induces c-Jun NH2-terminal kinase-dependent apoptosis and synergizes with tumor necrosis factor-related apoptosis-inducing ligand activity in human neoplastic cells of hematopoietic or endodermal origin. Ammirante M; Di Giacomo R; De Martino L; Rosati A; Festa M; Gentilella A; Pascale MC; Belisario MA; Leone A; Turco MC; De Feo V Cancer Res; 2006 Apr; 66(8):4385-93. PubMed ID: 16618764 [TBL] [Abstract][Full Text] [Related]
16. Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells. Woods DC; Alvarez C; Johnson AL Gynecol Oncol; 2008 Mar; 108(3):632-40. PubMed ID: 18191995 [TBL] [Abstract][Full Text] [Related]
17. Synergistic anti-cancer effects via co-delivery of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) and doxorubicin using micellar nanoparticles. Lee AL; Dhillon SH; Wang Y; Pervaiz S; Fan W; Yang YY Mol Biosyst; 2011 May; 7(5):1512-22. PubMed ID: 21350763 [TBL] [Abstract][Full Text] [Related]
18. Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines. Robson H; Meyer S; Shalet SM; Anderson E; Roberts S; Eden OB Med Pediatr Oncol; 2002 Dec; 39(6):573-80. PubMed ID: 12376980 [TBL] [Abstract][Full Text] [Related]
19. [Synergistic effects and mechanisms of combined tumor necrosis factor-related apoptosis-inducing ligand and chemotherapeutic drugs or radiotherapy in killing laryngeal squamous carcinoma cells in vitro]. Zhang M; Zhou L Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Jul; 44(7):565-70. PubMed ID: 19957654 [TBL] [Abstract][Full Text] [Related]
20. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes. Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Jiang X Nanotechnology; 2011 Jul; 22(26):265105. PubMed ID: 21586819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]